In summary, our study showed that the examination of PTPN12 expression by IHC could serve as an effective tool in identifying those NPC patients at increased risk of tumor invasiveness and metastasis, and also elaborate decreased PTPN12 expression as a novel adverse independent prognostic factor in NPC, which may help us find new therapeutic target. Here, PTPN12 is linked to neoplasm.